Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous elamipretide in stable heart failure with reduced ejection fraction
2014-005724-10Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Jan 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing Elamipretide with Placebo (2 arms). Primary endpoint: Change from baseline in left ventricular end systolic volume. Started Jan 2016; status: completed.
02
Drugs
elamipretide
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2014-005724-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005724-10.